Dataset Information


Whole exome sequencing analyses of human, IDH2-mutated, acute myeloid leukemia samples from patients before or during treatment with Enasidenib.

ABSTRACT: Mutations in isocitrate dehydrogenase 2 (IDH2) occur in many cancers including Acute Myeloid Leukemia (AML). In preclinical models mutant IDH2 causes partial hemopoietic differentiation arrest. Recently, we showed that single agent Enasidenib, a first-in-class, selective mutant IDH2 inhibitor, produces a 40% response in relapsed/refractory AML patients by promoting differentiation. Yet, the rate, extend and duration of the clinical benefits of Enasidenib vary from one patient to another. To investigate how the genetic mutational landscape, at baseline or at relapse, contributes in modulating response to Enasidenib, WES analyses on FACS-sorted blasts from baseline, best response and/or relapse samples from 16 Enasidenib-treated patients were performed. WES analyses were also performed on the CD3+ cells from the same patients, which may be used as germinal control samples.

INSTRUMENT(S): Illumina HiSeq 2000

ORGANISM(S): Homo sapiens  


PROVIDER: E-MTAB-6299 | ArrayExpress | 2018-08-13



altmetric image


Mutations in the gene encoding isocitrate dehydrogenase 2 (IDH2) occur in several types of cancer, including acute myeloid leukemia (AML). In model systems, mutant IDH2 causes hematopoietic differentiation arrest. Enasidenib, a selective small-molecule inhibitor of mutant IDH2, produces a clinical response in 40% of treated patients with relapsed/refractory AML by promoting leukemic cell differentiation. Here, we studied the clonal basis of response and acquired resistance to enasidenib treatmen  ...[more]

Similar Datasets

2018-01-01 | S-EPMC6925974 | BioStudies
2019-01-01 | S-EPMC6384189 | BioStudies
1000-01-01 | S-EPMC5465954 | BioStudies
2018-08-08 | E-MTAB-6660 | ArrayExpress
2011-01-01 | S-EPMC3883450 | BioStudies
2018-01-01 | S-EPMC6041864 | BioStudies
2016-01-01 | S-EPMC5050039 | BioStudies
2017-01-01 | S-EPMC5572791 | BioStudies
2010-01-01 | S-EPMC2881719 | BioStudies
2020-01-01 | S-EPMC7407265 | BioStudies